EMAIL THIS PAGE TO A FRIEND

The Journal of biological chemistry

An Early and Robust Activation of Caspases Heads Cells for a Regulated Form of Necrotic-like Cell Death.


PMID 26124276

Abstract

Apoptosis is triggered by the activation of caspases and characterized by chromatin condensation and nuclear fragmentation (type II nuclear morphology). Necrosis is depicted by a gain in cell volume (oncosis), swelling of organelles, plasma membrane leakage, and subsequent loss of intracellular contents. Although considered as different cell death entities, there is an overlap between apoptosis and necrosis. In this sense, mounting evidence suggests that both processes can be morphological expressions of a common biochemical network known as "apoptosis-necrosis continuum." To gain insight into the events driving the apoptosis-necrosis continuum, apoptotically proficient cells were screened facing several apoptotic inducers for the absence of type II apoptotic nuclear morphologies. Chelerythrine was selected for further studies based on its cytotoxicity and the lack of apoptotic nuclear alterations. Chelerythrine triggered an early plasma membrane leakage without condensed chromatin aggregates. Ultrastructural analysis revealed that chelerythrine-mediated cytotoxicity was compatible with a necrotic-like type of cell death. Biochemically, chelerythrine induced the activation of caspases. Moreover, the inhibition of caspases prevented chelerythrine-triggered necrotic-like cell death. Compared with staurosporine, chelerythrine induced stronger caspase activation detectable at earlier times. After using a battery of chemicals, we found that high concentrations of thiolic antioxidants fully prevented chelerythrine-driven caspase activation and necrotic-like cell death. Lower amounts of thiolic antioxidants partially prevented chelerythrine-mediated cytotoxicity and allowed cells to display type II apoptotic nuclear morphology correlating with a delay in caspase-3 activation. Altogether, these data support that an early and pronounced activation of caspases can drive cells to undergo a form of necrotic-like regulated cell death.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB4503280
Anti-CASP2 (p18, Cleaved-Gly170) antibody produced in rabbit, affinity isolated antibody
SAB4503281
Anti-CASP2 (p18, Cleaved-Thr325) antibody produced in rabbit, affinity isolated antibody
SAB4503279
Anti-CASP2 antibody produced in rabbit, affinity isolated antibody
SAB4503332
Anti-CASP9 antibody produced in rabbit, affinity isolated antibody
SAB4503333
Anti-CASP9 antibody produced in rabbit, affinity isolated antibody
SAB4503334
Anti-CASP9 antibody produced in rabbit, affinity isolated antibody
SAB4503335
Anti-CASP9 antibody produced in rabbit, affinity isolated antibody
SAB4300683
Anti-Caspase 9 antibody produced in rabbit, affinity isolated antibody
PRS3447
Anti-Caspase-2 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB3500405
Anti-Caspase-9 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
610046
Boron-11B, 95 atom % 11B
11B
C3915
Colchicine, BioReagent, plant cell culture tested, ≥95% (HPLC)
C22H25NO6
WH0000835M10
Monoclonal Anti-CASP2 antibody produced in mouse, clone 1C11, purified immunoglobulin, buffered aqueous solution
WH0000842M1
Monoclonal Anti-CASP9 antibody produced in mouse, clone 3B8-4G2, purified immunoglobulin, buffered aqueous solution
SAB1403634
Monoclonal Anti-CASP9 antibody produced in mouse, clone 4F12-G6, purified immunoglobulin, buffered aqueous solution
C4356
Monoclonal Anti-Caspase 9 antibody produced in mouse, ~2 mg/mL, clone CAS9, purified immunoglobulin, buffered aqueous solution